

Saint Vincent and the Grenadines

Tuberculosis profile

Population 2016

<1 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–<0.01)	2 (2–2.1)
Mortality (HIV+TB only)	0 (0–0)	0 (0–0)
Incidence (includes HIV+TB)	<0.01 (<0.01–<0.01)	6.3 (5.4–7.3)
Incidence (HIV+TB only)	0 (0–0)	0 (0–0)
Incidence (MDR/RR-TB)**	<0.01 (0–<0.01)	3.2 (0–7.6)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0 (0–0)	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)
Males	0 (0–0)	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)
Total	<0.01 (0–<0.01)	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)

TB case notifications, 2016

Total cases notified	7
Total new and relapse	6
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	117%
- % pulmonary	100%
- % bacteriologically confirmed among pulmonary	100%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.33 (0.28–0.38)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			3 (0–7)
Estimated % of TB cases with MDR/RR-TB	50% (1.3–99)	0% (0–98)	
% notified tested for rifampicin resistance	100%		6
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size

	Success	Cohort
New cases registered in 2015		
Previously treated cases registered in 2015		
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014		
XDR-TB cases started on second-line treatment in 2014		

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2017

National TB budget (US\$ millions)


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive

— MDR/RR-TB

— XDR-TB